Michelson Diagnostics Limited

Early Stage

Michaelson Diagnostics Limited develops imaging products using a technology called Multi-Beam Optical Coherence Tomography (OCT).  This technology enables in-vivo capture, visualisation and measurement of histopathology details that are too small to be seen with ultrasound, and too deep for conventional microscopy.  It provides a unique way for a dermatologist to see detailsof a skin lesion quickly and non-invasively, so that earlier, more accurate, lower cost and less invasive treatments with a better clinical outcome can be applied and the progress of the treatment easily monitored.  The Company's current VivoSight OCT scanner with hand-held probe is CE approved in Europe and has 510(k) FDA clearance in the USA for clinical use in dermatology clinics.

Though a platform technology, the Company's initial focus is on the diagnosis and treatment of Non-melanoma Skin Cancer which represents a very large market in which the advantages to both patients and dermatologists can be clealy demonstrated.

Our investment has supported the development, regulatory approvals and initial commercial traction of the company's devices.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200